心力衰竭住院患者肾功能与结局
该研究基于GWTG-HF注册登记2014至2019年418家中心365,494例心衰住院患者,按出院eGFR分层评估指南导向药物治疗及入院eGFR与院内死亡的关系。结果显示eGFR越低,指南导向药物治疗使用率越低,院内死亡率呈阶梯式升高。
要点
- 出院eGFR<60 ml/min/1.73 m2者占64%,透析者占5%。
- 射血分数降低心衰中,eGFR越低三联治疗使用率越低(p<0.001)。
- 入院eGFR越低院内死亡率越高,呈阶梯式升高(p<0.001)。
核心结论
- 合并肾功能不全的射血分数降低心衰患者死亡风险高,但未充分接受循证药物治疗,即使eGFR水平并非禁忌。
研究设计与样本
- 基于GWTG-HF注册登记2014至2019年418家中心365,494例心衰住院患者的回顾性队列分析。
主要发现
- 中位出院eGFR为51 ml/min/1.73 m2(四分位距34至72 ml/min/1.73 m2),234,332例(64%)eGFR<60 ml/min/1.73 m2,18,869例(5%)接受透析。
- eGFR分布2014至2019年保持稳定。
- 射血分数降低心衰(≤40%)患者中,出院eGFR<30 ml/min/1.73 m2或透析者β受体阻滞剂等指南导向药物治疗使用率最低(p<0.001)。
- 三联治疗(ACEI/ARB/ARNI+β受体阻滞剂+MRA)使用率在eGFR≥90、60至89、45至59、30至44、<30 ml/min/1.73 m2及透析组分别为38%、33%、25%、15%、5%和3%(p<0.001)。
- 院内死亡率随入院eGFR降低呈阶梯式升高,上述各组分别为1.1%、1.5%、2.0%、3.0%、5.0%和4.2%(p<0.001)。
临床怎么用
- 对合并肾功能不全的心衰住院患者,应评估指南导向药物治疗的适用性,避免因肾功能不全而过度停用循证药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few contemporary data exist evaluating care patterns and outcomes in heart failure (HF) across the spectrum of kidney function. OBJECTIVES: This study sought to characterize differences in quality of care and outcomes in patients hospitalized for HF by degree of kidney dysfunction. METHODS: Guideline-directed medical therapies were evaluated among patients hospitalized with HF at 418 sites in the GWTG-HF (Get With The Guidelines-Heart Failure) registry from 2014 to 2019 by discharge CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)-derived estimated glomerular filtration rate (eGFR). We additionally evaluated the risk-adjusted association of admission eGFR with in-hospital mortality. RESULTS: Among 365,494 hospitalizations (age 72 ± 15 years, left ventricular ejection fraction [EF]: 43 ± 17%), median discharge eGFR was 51 ml/min/1.73 m2 (interquartile range: 34 to 72 ml/min/1.73 m2), 234,332 (64%) had eGFR <60 ml/min/1.73 m2, and 18,869 (5%) were on dialysis. eGFR distribution remained stable from 2014 to 2019. Among 157,439 patients with HF with reduced EF (≤40%), discharge guideline-directed medical therapies, including beta-blockers, were lowest in discharge eGFR <30 mL/min/1.73 m2 or dialysis (p < 0.001). "Triple therapy" with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor + beta-blocker + mineralocorticoid receptor antagonist was used in 38%, 33%, 25%, 15%, 5%, and 3% for eGFR ≥90, 60 to 89, 45 to 59, 30 to 44, <30 ml/min/1.73 m2, and dialysis, respectively; p < 0.001. Mortality was higher in a graded fashion at lower admission eGFR groups (1.1%, 1.5%, 2.0%, 3.0%, 5.0%, and 4.2%, respectively; p < 0.001). Steep covariate-adjusted associations between admission eGFR and mortality were observed across EF subgroups, but was slightly stronger for HF with reduced EF compared with HF with mid-range or preserved EF (pinteraction = 0.045). CONCLUSIONS: Despite facing elevated risks of mortality, patients with comorbid HF with reduced EF and kidney disease are not optimally treated with evidence-based medical therapies, even at levels of eGFR where such therapies would not be contraindicated by kidney dysfunction. Further efforts are required to mitigate risk in comorbid HF and kidney disease.
引用
- Patel RB, Fonarow GC, Greene SJ, et al. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. J Am Coll Cardiol. 2021. PMID: 33989713. doi:10.1016/j.jacc.2021.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。